April 20, 2014 6:59 PM ET

Healthcare Equipment and Supplies

Company Overview of Accumetrics, Inc.

Company Overview

As of August 30, 2013, Accriva Diagnostics was acquired by Nexus Dx, Inc. Accumetrics, Inc. develops, manufactures, and markets the VerifyNow System, a suite of assays for the assessment of platelet function. Its VerifyNow System consists of an instrument and family of single-use tests to assess platelet response to antiplatelet medications. The company’s VerifyNow System includes VerifyNow P2Y12 Test, which measure the patient’s response to clopidogrel (Plavix), prasugrel (Effient), and ticlopidine (Ticlid); VerifyNow Aspirin Test, which utilizes arachidonic acid as the agonist to measure the effect of aspirin on platelet reactivity; and VerifyNow IIb/IIIa Test, which measures a patient’s r...

3985 Sorrento Valley Boulevard

San Diego, CA 92121

United States

Founded in 1996

Phone:

858-643-1600

Fax:

858-643-1605

Key Executives for Accumetrics, Inc.

Accumetrics, Inc. does not have any Key Executives recorded.

Accumetrics, Inc. Key Developments

Accumetrics, Inc. Obtains CE Mark for Therapeutic Window Claim on the VerifyNow P2Y12 Test

Accumetrics, Inc. announced an expansion in the intended use for the CE marked VerifyNow P2Y12 Test. Physicians can now use the test results to assess whether a patient may be at greater risk for both bleeding or ischemic events, as an aid to manage therapeutic treatment decisions and accurately assess the antiplatelet effect from P2Y12 inhibitors (such as clopidogrel, prasugrel and ticagrelor). The expanded claim was developed based on the ADAPT-DES registry (8500 patients using the VerifyNow system), which validated the existence of a therapeutic window. The data demonstrated that patients with a P2Y12 Reaction Units (PRU) result of >=208 were at a significantly increased risk of cardiovascular events and patients with a PRU of <95 were receiving virtually no additional protection from cardiovascular events, but at a significantly increased risk of bleeding. Previous studies have demonstrated the association between PRU and increased risk for recurrent ischemic and bleeding events. However, most of those studies were too small to warrant a label change for the VerifyNow P2Y12 Test. With the large number of patients, and real-world patient population represented in ADAPT-DES, there was significant evidence to proceed with a CE marked claim. The addition of the therapeutic window claim marks the second major change to the intended use of the CE marked VerifyNow P2Y12 Test in the last two years. With a similar claim currently being reviewed by the FDA, Accumetrics is on track to have the first platelet reactivity test with a claim in the U.S. and the EU to assess risk of both bleeding and ischemic events.

Accumetrics, Inc. Announces 8500+ Patient Trial Validates Association Between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012

Accumetrics, Inc. announced the presentation of the 1-year results from the Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) registry at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) meeting. Study findings indicate a significant association between platelet reactivity and 12-month stent thrombosis, myocardial infarction, and death. ADAPT-DES had previously demonstrated an approximately four times greater rate of stent thrombosis at 30-days in patients with high residual platelet reactivity (HRPR), as measured by Accumetrics' VerifyNow P2Y12 Test. This association continued through follow-up, as patients with HRPR demonstrated a 2.5 times greater rate of stent thrombosis at 1-year. The VerifyNow P2Y12 Test and VerifyNow PRUTest are used to measure a patient's platelet reactivity and the antiplatelet effect of medications such as clopidogrel and prasugrel (Plavix(R) and Effient(R)). Much like the commonly used PT/INR, there has been great interest within the cardiology community to identify levels of platelet reactivity where the risk for both thrombotic events and bleeding are minimized. The VerifyNow P2Y12 Test and the VerifyNow PRUTest represent the first clinically available, rapid and easy-to-use point-of-care system for measuring the level of P2Y12 receptor blockade.

Accumetrics, Inc. Presents at Lazard Capital Markets, LLC's 9th Annual Healthcare Conference, Nov-14-2012 09:30 AM

Accumetrics, Inc. Presents at Lazard Capital Markets, LLC's 9th Annual Healthcare Conference, Nov-14-2012 09:30 AM. Venue: The Pierre Hotel, 2 East 61st Street, New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
Invisible Sentinel, Inc. United States
Primus Corporation United States
The Trylon Corporation United States
Rx Timer Cap, LLC United States
Sinopsys Surgical, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
August 30, 2013
--
Private Placement
August 29, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Accumetrics, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.